Order results by:
| Issue | Title | |
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... of clopidogrel play an important role in the resistance development. Allel variants of the gene cytochrome CYP2C ..." | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... for resistance to antiplatelet therapy with clopidogrel. The decrease in the effectiveness of prolonged therapy ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| "... The ACC/AHA clopidogrel clinical alert about the possibility of ineffective treatment ..." | ||
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well ..." | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... of clopidogrel’s active metabolite and, respectively, its antiplatelet effect. We sought to determine the impact ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..." | ||
| Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
| E. N. Dankovtseva, D. A. Zateyshchikov | ||
| "... The possibilities and evidence base of clopidogrel use in clinical practice are discussed. Data ..." | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... underwent CYP2C19 PhGT aimed at antiplatelet therapy personalization. Results. According to CYP2C19 ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| "... Aim. To analyze the literary and own data about clopidogrel influence on platelets during ..." | ||
| Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
| O. V. Gaisenok | ||
| "... in patients with cardioascular diseases are discussed. Role of clopidogrel in contemporary antiplatelet ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have ..." | ||
| Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
| V. A. Sulimov, E. V. Moroz | ||
| "... during clopidogrel therapy can be usefull for timely correction of antiplatelet therapy. Increase ..." | ||
| Vol 11, No 1 (2015) | EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Andreev, D. A. Sychev | ||
| "... Evaluation of platelet function with subsequent modification of antiplatelet therapy regimen ..." | ||
| Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. V. Rudakova, N. V. Lomakin | ||
| "... Dual antiplatelet therapy, including clopidogrel and aspirin, in a significant share of patients ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| "... to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings ..." | ||
| Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
| "... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel ..." | ||
| Vol 7, No 5 (2011) | HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY | similar documents |
| G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio | ||
| "... Введение. Полученные ранее данные свидетельствуют о наличии у клопидогрела не только ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients ..." | ||
| Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
| "... and combined antiplatelet therapy (acetylsalicylic acid and clopidogrel). Material and methods. 98 patients ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... Aim. To study a rate of clopidogrel use in patients having indications for clopidogrel therapy ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... antiplatelet therapy with acetyl salicylic acid and clopidogrel. Numerous clinical characteristics ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment ..." | ||
| Vol 7, No 1 (2011) | THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY | Abstract similar documents |
| V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev | ||
| "... Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... and induced flow cytofluorometry during antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA ..." | ||
| Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
| "... Aim. To evaluate the incidence of acetylsalicylic acid (ASA) and clopidogrel resistance ..." | ||
| Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
| "... . The risk of HRPR to clopidogrel is higher in 681A CYP2C19 allele carriers compared to the G681 carriers ..." | ||
| Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
| A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
| "... Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual ..." | ||
| Vol 13, No 5 (2017) | INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION | Abstract similar documents |
| E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash | ||
| "... Aim. To study the effect of replacing clopidogrel with ticagrelor on endpoints of hospital period ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... , warfarin, ticlopidine and clopidogrel are discussed. Study data on new antiplatelet drugs are given ..." | ||
| Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
| "... Aim. To evaluate an adequacy of dual antiplatelet therapy (DAPT) in patients with acute coronary ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... Aim. To study a rate of resistance to acetylsalicylic acid (ASA) and clopidogrel and clinical ..." | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... genes with the development of resistance to antiplatelet drugs in CHD patients. Material and Methods ..." | ||
| Vol 10, No 6 (2014) | СONCOMITANT ADMINISTRATION OF CLOPIDOGREL AND PROTON PUMP INHIBITORS: ARE THERE ANY OPEN QUESTIONS LEFT TODAY? | Abstract similar documents |
| S. Yu. Martsevich, A. Yu. Suvorov | ||
| "... Concomitant administration of clopidogrel and proton pump inhibitors (PPI), the possible influence ..." | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... . In addition to endovascular treatment, dual antiplatelet therapy plays a key role in the treatment ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... ), encoding P-glycoprotein, in pharmacotherapy with digoxin, antiplatelet drugs (clopidogrel tikagrelol ..." | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... of revealed disorders with antiplatelet agent — clopidogrel 75 mg/day. Material and methods. 40 patients ..." | ||
| Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
| N. В. Perepech, A. V. Tregubov | ||
| "... Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test ..." | ||
| Vol 14, No 2 (2018) | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. В. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, K. O. Tsukanova | ||
| "... in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74 ..." | ||
| Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
| K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
| "... antiplatelet drugs (acetylsalicylic acid and clopidogrel) and heparin. There were not any reasons ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... (3.8%) patients. Aspirin was the only antiplatelet agent in 3 cases and clopidogrel – in one case ..." | ||
| Vol 14, No 6 (2018) | P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel | Abstract PDF (Eng) similar documents |
| N. M. Vorobyeva | ||
| "... with clopidogrel or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves ..." | ||
| Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
| I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
| "... method in the first day of ACS before antiplatelet therapy and on day 10. Results. Increase ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... therapy (TAT), selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet ..." | ||
| Vol 14, No 6 (2018) | Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation | Abstract PDF (Eng) similar documents |
| A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee | ||
| "... pharmacies. Among antiplatelet agents, aspirin was available in most pharmacies, and clopidogrel was mostly ..." | ||
| Vol 6, No 1 (2010) | ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors ..." | ||
| Vol 18, No 5 (2022) | The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case | Abstract similar documents |
| O. V. Gaisenok, Yu. M. Chichkov, M. V. Leonova | ||
| "... Background. Combination therapy with two antiplatelet agents (ticagrelor or clopidogrel plus ..." | ||
| Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
| S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
| "... of use of acetylsalicylic acid, clopidogrel, statins, beta-blockers, ACE inhibitors, angiotensin II ..." | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern therapy of atherosclerosis ..." | ||
| Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
| I. N. Bokarev, L. V. Popova | ||
| "... is highlighted. ASA modes of action and its position among the modern antiplatelet agents are considered ..." | ||
| Vol 15, No 3 (2019) | Study of the Association of V640L (rs6133) Polymorphism in the Platelet P-selectin Gene with Acetylsalicylic Acid Resistance in Patients after Coronary Bypass Surgery | Abstract similar documents |
| A. A. Kosinova, T. S. Mongush, M. D. Goncharov, T. N. Subbotina, K. S. Semashchenko, G. Y. Kochmareva, Yu. I. Grinshtein | ||
| "... were confirmed by coronary angiography. The antiplatelet therapy was stopped for at least 5 days before ..." | ||
| Vol 9, No 1 (2013) | OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS | Abstract PDF (Eng) similar documents |
| S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, M. M. Lukyanov, N. N. Nikulina, A. V. Zagrebelny, A. N. Vorobyov, K. G. Pereverseva, E. A. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. E. Serdyuk, М. S. Kharlap | ||
| "... : antiplatelet agents – in 60.4% of the cases (584 patients received acetylsalicylic acid and 20 – clopidogrel ..." | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... Prerequisites for the prolonged dual antiplatelet therapy after myocardial infarction are presented ..." | ||
| Vol 9, No 6 (2013) | ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? | Abstract similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein | ||
| "... heart disease after percutaneous coronary intervention and its contribution to antiplatelet therapy ..." | ||
| Vol 8, No 4 (2012) | ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin | ||
| "... Alternative approaches to the use of two component antiplatelet therapy in patients with acute ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| "... recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83 ..." | ||
| Vol 10, No 6 (2014) | THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY | Abstract similar documents |
| D. A. Andreev | ||
| "... complications in patients receiving antiplatelet therapy is presented. Indications for antiplatelet therapy ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT ..." | ||
| Vol 18, No 4 (2022) | The effect of rs776746 polymorphism in the CYP3A5 gene on heart rate when using bisoprolol in patients with acute coronary syndrome | Abstract similar documents |
| V. A. Shumkov, K. A. Zagorodnikova, S. A. Boldueva, A. A. Murzina | ||
| "... Aim. The aim of this work was to study the occurrence of the rs776746 allelic variant of the CYP3A ..." | ||
| Vol 14, No 4 (2018) | Role of Single Nucleotide Polymorphism of СУР17А Gene in the Development of Stroke | Abstract similar documents |
| S. Yu. Nikulina, V. A. Shulman, A. A. Chernova, D. A. Nikulin, A. A. Semenchukov, O. V. Marilovceva, S. S. Tret'jakova, I. I. Lebedeva, V. N. Maksimov | ||
| "... CYP17A1 is one of the many genes that can participate in the formation of predisposition ..." | ||
| Vol 17, No 4 (2021) | Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Zh. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. A. Grishina, D. A. Sychev | ||
| "... therapy in patients with CYP2C9*2 (430C>T) rs179985 and CYP2C9*3 (1075A>C) rs1057910 gene polymorphisms ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| Vol 4, No 1 (2008) | COMPARISON OF ANTIPLATELET EFFECT AND SAFETY OF ORIGINAL DRUG «ASPIRIN CARDIO» AND GENERIC«ACECARDOL» IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE | Abstract similar documents |
| N. A. Belolipetskiy, S. N. Tolpygina, O. А. Litinskaya, V. G. Belolipetskaya, S. Yu. Martsevich | ||
| "... Aim. To compare antiplatelet effect of two acetylsalicylic acid medicines, Acecardol ("Synthesis ..." | ||
| Vol 15, No 5 (2019) | Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry | Abstract similar documents |
| Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan | ||
| "... of Cardiology (ESC), patients with coexisting AF and ACS should receive dual antiplatelet therapy ..." | ||
| Vol 7, No 6 (2011) | PHARMACOTHERAPY ANALYSIS OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION IN HOSPITALS OF VARIOUS TYPES | Abstract similar documents |
| R. M. Magdeev, O. V. Reshetko, E. Y. Rudnichenko, N. V. Furman, P. V. Dolotovskaya, T. Y. Grozdova, L. N. Volkova | ||
| "... , and clopidogrel was not prescribed. At the same hospital clotting time was determined for monitoring of heparin ..." | ||
| Vol 7, No 6 (2011) | CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM | Abstract similar documents |
| Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov | ||
| "... therapy (acetylsalicylic acid, clopidogrel, warfarin) was made on the 4th day of disease onset taking ..." | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... of antiplatelet and/or anticoagulant drugs is a complicating factor in invasive and surgical procedures ..." | ||
| Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF ACIDUM ACETYLSALICYLICUM USAGE | Abstract similar documents |
| V. N. Drozdov, V. A. Kim | ||
| "... Data about efficacy and safety of acetylsalicylic acid usage as antiplatelet drug and for cancer ..." | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents ..." | ||
| Vol 16, No 3 (2020) | A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study | Abstract similar documents |
| N. V. Lomakin, L. I. Buryachkovskaya, D. A. Zolin, V. I. Kazey | ||
| Vol 9, No 5 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... efficiency of present antiplatelet and anticoagulant drugs is shown in the key of preventing PAD thrombotic ..." | ||
| Vol 19, No 6 (2023) | Platelet phenotypes and practical aspects of platelet function testing in cardiology | Abstract similar documents |
| Zh. D. Kobalava, A. S. Pisaryuk, A. A. Filkova, E. S. Tukhsanboev, A. A. Boldyreva, D. P. Lazutova, I. A. Meray, M. A. Panteleev | ||
| "... the various consensus papers on assessing thrombotic and bleeding risk, monitoring antiplatelet therapy ..." | ||
| Vol 12, No 5 (2016) | Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms | Abstract PDF (Eng) similar documents |
| Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev | ||
| "... Aim. To evaluate treatment adherence and prevalence of CYP2C9 and VKORC1 gene mutations ..." | ||
| Vol 13, No 4 (2017) | GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS | Abstract similar documents |
| M. A. Vorobyeva, M. M. Azova, O. O. Gigani, I. V. Garmash, S. V. Villevalde, Zh. D. Kobalava | ||
| "... , 62.1% of men) were included into the study. Polymorphism Phe189Ser of the CYP3A4 (gene encoding ..." | ||
| Vol 14, No 1 (2018) | NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Ju. P. Skirdenko, N. A. Nikolayev | ||
| "... , polymorphism of genes CYP2C9 and VKORC1 and the structure of food preferences. Results. Persons ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| Vol 3, No 2 (2007) | VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY | Abstract similar documents |
| D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes | ||
| "... of polymorphisms of genes of their biotransformation (CYP2C9) and molecule-targets (VKORC1). This created basis ..." | ||
| Vol 17, No 1 (2021) | Pharmacogenetics as a Way for Personalizing Diuretic Therapy: Focus on Torasemide | Abstract similar documents |
| N. M. Gafurova, E. V. Shikh, O. D. Ostroumova | ||
| "... B1 polymorphism is approximately 15.5%, the CYP2C9 polymorphism is 20%, and the OAT1 and OAT4 ..." | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP ..." | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... of CYP2C9 and VKORC1 genes mutations were determined at the initial examination. These indicators were ..." | ||
| Vol 6, No 6 (2010) | COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR) | Abstract similar documents |
| S. Yu. Martsevich, S. N. Tolpygina, E. S. Boychenko, R. E. Dubinskaya, Yu. V. Lukina, V. P. Voronina | ||
| "... Aim. To compare the antiplatelet efficacy of the original and generic enterosoluble tableted ..." | ||
| Vol 20, No 6 (2024) | Platelet reactivity clinical and biochemical markers when taking acetylsalicylic acid as part of dual antiplatelet therapy in the myocardial infarction subacute period | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, A. V. Kapytski | ||
| "... antiplatelet therapy. Material and methods. 405 patients with MI (79.5% men and 20.5% women, average age 58 ..." | ||
| Vol 20, No 3 (2024) | Use of glycoprotein IIb/IIIa inhibitors in myocardial infarction in the Russian Federation, according to the Russian Registry of Acute Myocardial Infarction REGION-IM | Abstract similar documents |
| N. S. Kostritca, R. M. Rabinovich, R. M. Shakhnovich, I. S. Yavelov, R. G. Gulyan, Yu. K. Rytova, S. N. Tereschenko, A. D. Erlikh, D. V. Pevzner | ||
| Vol 21, No 2 (2025) | Myocardial infarction and embolism: a rare combination associated with a poor prognosis (a clinical case) | Abstract similar documents |
| O. L. Lyakhovich, O. V. Filyushin, S. S. Yakushin | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... metabolized by CYP3A4 with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2 isoenzymes ..." | ||
| Vol 15, No 3 (2019) | Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population | Abstract similar documents |
| K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev | ||
| "... ", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «CYP2C19 ..." | ||
| Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
| "... in trials and proven efficacy in the prevention of stroke/systemic embolism, the use of clopidogrel ..." | ||
| Vol 9, No 6 (2013) | THROMBOLYSIS OR PRIMARY PCI FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION? THE STREAM TRIAL (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION) | Abstract similar documents |
| V. A. Sulimov | ||
| "... by half in patients aged ≥75 years) in combination with clopidogrel and enoxaparin followed by admission ..." | ||
| Vol 14, No 1 (2018) | COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015 | Abstract similar documents |
| O. V. Reshetko, A. V. Sokolov, E. V. Rykalina, N. V. Furman | ||
| "... receptors (AMCR), diuretics, oral anticoagulants, clopidogrel increased (p<0.05). In the structure ..." | ||
| Vol 16, No 5 (2020) | Treatment of Patients with Acute Coronary Syndrome with ST Segment Elevation in Clinical Practice of the Republic of Karelia: the Results of 10-year Register | Abstract similar documents |
| I. S. Skopets, N. N. Vezikova, A. V. Malafeev, A. N. Malygin, V. A. Litvinova | ||
| "... .8% – clopidogrel, 91.1% – anticoagulants, 91.6% – beta-blockers, 95.6% – statins, 94.2% – angiotensin-converting ..." | ||
| Vol 17, No 1 (2021) | Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease | Abstract similar documents |
| S. K. Zyryanov, S. B. Fitilev, A. V. Vozzhaev, I. I. Shkrebniova | ||
| "... /clopidogrel/oral anticoagulants – 95,7%, statins/ezetimibe – 86,3%, angiotensin-converting enzyme inhibitors ..." | ||
| Vol 8, No 2 (2012): | РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА БЕЗ СТОЙКОГО ПОДЪЕМА СЕГМЕНТА ST | Abstract similar documents |
| , , , , , , , , , , , , , , , , | ||
| Vol 11, No 5 (2015) | Practical aspects of apixaban use in clinical practice: continuing the theme | Abstract similar documents |
| S. N. Bel'diev | ||
| "... Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 ..." | ||
| Vol 17, No 5 (2021) | Pharmacogenetic Aspects of Postoperative Anesthesia with Ketoprofen in Cardiac Surgery Patients | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Z. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. А. Grishina, D. A. Sychev | ||
| "... Aim. Evaluation of the effect of polymorphisms of the CYP2D6, CYP2C8 genes on the efficacy ..." | ||
| Vol 6, No 5 (2010) | THE CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY 2010 IN STOCKHOLM: NEWS FOR PRACTITIONERS | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... significant events of the Congress are discussed. Symposia on antiplatelet therapy, hypertension, and recently ..." | ||
| Vol 4, No 2 (2008) | BETA-ADRENOBLOCKERS AND PLATELET AGGREGATION. CARVEDILOL | Abstract similar documents |
| A. N. Zakirova, F. S. Zarudij, B. N. Garifullin | ||
| "... . The current view on of beta-blocker antiplatelet effects is presented on the basis of physical and chemical ..." | ||
| 1 - 100 of 163 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
